Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Public ClinicalTrials.gov record NCT03833167. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).
Study identification
- NCT ID
- NCT03833167
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 450 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1, 2019 (Actual)
- Primary completion
- Jun 28, 2024 (Actual)
- Completion
- Jan 20, 2026 (Actual)
- Last update posted
- Sep 28, 2026
2019 – 2026
United States locations
- U.S. sites
- 30
- U.S. states
- 21
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama, Mitchell Cancer Institute ( Site 1562) | Mobile | Alabama | 36604 | — |
| City of Hope Medical Center ( Site 1505) | Duarte | California | 91010 | — |
| UCSD Moores Cancer Center ( Site 1561) | La Jolla | California | 92093-0698 | — |
| UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1568) | Los Angeles | California | 90095 | — |
| University of California Davis Comprehensive Cancer Center ( Site 1560) | Sacramento | California | 95817 | — |
| Stanford University Medical Center ( Site 1503) | Stanford | California | 94305 | — |
| University of Colorado Cancer Center ( Site 1506) | Aurora | Colorado | 80045 | — |
| Smilow Cancer Center at Yale-New Haven ( Site 1507) | New Haven | Connecticut | 06510 | — |
| Boca Raton Regional Hospital ( Site 1551) | Boca Raton | Florida | 33486 | — |
| UF Health ( Site 1511) | Gainesville | Florida | 32608 | — |
| University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1544) | Miami | Florida | 33136 | — |
| Winship Cancer Institute of Emory University ( Site 1512) | Atlanta | Georgia | 30322-1013 | — |
| Indiana University Melvin and Bren Simon Cancer Center ( Site 1515) | Indianapolis | Indiana | 46202 | — |
| University of Iowa Hospital and Clinics ( Site 1514) | Iowa City | Iowa | 52242 | — |
| University of Kentucky School of Medicine & Hospitals ( Site 1542) | Lexington | Kentucky | 40536 | — |
| Massachusetts General Hospital ( Site 1518) | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Center ( Site 1519) | Boston | Massachusetts | 02215 | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 1526) | Hackensack | New Jersey | 07601 | — |
| Northwell Health/ RJ Zuckerberg Cancer Center-Medical Oncology ( Site 1565) | Lake Success | New York | 11042 | — |
| Icahn School of Medicine at Mount Sinai ( Site 1575) | New York | New York | 10029 | — |
| Cleveland Clinic ( Site 1541) | Cleveland | Ohio | 44195 | — |
| Providence Portland Medical Center ( Site 1530) | Portland | Oregon | 97213 | — |
| UPMC Hillman Cancer Center ( Site 1570) | Pittsburgh | Pennsylvania | 15232 | — |
| MUSC Hollings Cancer Center ( Site 1533) | Charleston | South Carolina | 29425 | — |
| West Cancer Center - East Campus ( Site 1535) | Germantown | Tennessee | 38138 | — |
| Vanderbilt Ingram Cancer Center ( Site 1543) | Nashville | Tennessee | 37232 | — |
| The University of Texas-MD Anderson Cancer Center ( Site 1536) | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute ( Site 1537) | Salt Lake City | Utah | 84112 | — |
| Inova Schar Cancer Institute ( Site 1538) | Fairfax | Virginia | 22031 | — |
| West Virginia University ( Site 1569) | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03833167, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03833167 live on ClinicalTrials.gov.